Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle modification, produces clinically significant and sustained mean body weight reductions of 14–16% in adults without type 2 diabetes and 9.6% in adults with type 2 diabetes.
If you have obesity or overweight with a related health issue (like high blood pressure or diabetes) and lifestyle changes alone haven't worked, talk to your doctor about semaglutide 2.4 mg. It is a once-weekly injection taken alongside a healthy diet and exercise. It is not a substitute for lifestyle changes but helps overcome the body's natural tendency to regain weight. Be aware of potential side effects and that the dose starts low and increases gradually to help your body adjust.
Clinically significant and sustained mean reductions in body weight of 14–16% in participants without type 2 diabetes (T2D) and 9.6% in people with T2D were observed in the phase 3 Semaglutide Treatment Effect in People with obesity (STEP) 1–5 trials...
Why this rating
Based on phase 3 STEP 1-5 trials, which are large, placebo-controlled clinical trials.
Source
Integrating semaglutide into obesity management – a primary care perspective
Janine V. Kyrillos et al. · Postgraduate Medicine · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →